Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease

@article{Deleu2002ClinicalPA,
  title={Clinical Pharmacokinetic and Pharmacodynamic Properties of Drugs Used in the Treatment of Parkinson’s Disease},
  author={D. Deleu and M. G. Northway and Y. Hanssens},
  journal={Clinical Pharmacokinetics},
  year={2002},
  volume={41},
  pages={261-309}
}
Current research in Parkinson’s disease (PD) focuses on symptomatic therapy and neuroprotective interventions. Drugs that have been used for symptomatic therapy are levodopa, usually combined with a peripheral decarboxylase inhibitor, synthetic dopamine receptor agonists, centrally-acting antimuscarinic drugs, amantadine, monoamine oxidase-B (MAO-B) inhibitors and catechol-O-methyltransferase (COMT) inhibitors. Drugs for which there is at least some evidence for neuroprotective effect are… Expand
Pharmacokinetic Optimisation in the Treatment of Parkinson’s Disease
  • D. Nyholm
  • Medicine
  • Clinical pharmacokinetics
  • 2006
[A current view on dopamine receptor agonists in the treatment of Parkinson's disease].
  • N. Titova
  • Medicine
  • Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova
  • 2015
Pharmacokinetic-Pharmacodynamic Modeling of Levodopa in Patients With Advanced Parkinson Disease
Role of integrative pharmacokinetic and pharmacodynamic optimization strategy in the management of Parkinson"s disease patients experiencing motor fluctuations with levodopa.
  • C. Okereke
  • Medicine
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2002
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 295 REFERENCES
Clinical Pharmacokinetics of Anti-Parkinsonian Drugs
Clinical Pharmacology of Dopamine Agonists in Parkinson’s Disease
Antiparkinsonian Agents
Pramipexole — a new dopamine agonist for the treatment of Parkinson's disease
Concentration-Effect Relationship of Levodopa in Patients with Parkinson’s Disease
Clinical Pharmacokinetics of Ropinirole
...
1
2
3
4
5
...